AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00036023
Drug: darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04973904
Drug: Toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT04973904
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV infusion
Trial: NCT04973904
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT04973904
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV infusion
Trial: NCT06452342
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid 1.5 grams, orally, three times a day during menstrual cycle for the 3 month study period
Trial: NCT05727969
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine at a a rate of 0.5 μg/kg/hour will be infused with induction of anesthesia.
Trial: NCT05727969
Drug: Lactated Ringer
RxNorm normalized name: lactated ringers
DrugBank: COVID-19 Nucleocapsid-GM-CSF Protein Lactated Ringer's Injection (DB15845)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactated ringer solution at a a rate of 0.5 μg/kg/hour will be infused with induction of anesthesia.
Trial: NCT06132243
Drug: Jaktinib Hydrochloride Tablets
RxNorm normalized name: sevelamer hydrochloride Oral Tablet
DrugBank: Jaktinib (DB17545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally, one tablet at a time
Trial: NCT04821063
Drug: Moxifloxacin Hydrochloride
RxNorm normalized name: Moxifloxacin Hydrochloride
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose: 400 mg; Dosage form: tablet; Route of administration: oral
Trial: NCT04788017
Drug: Ziresovir
RxNorm normalized name: Ziresovir
DrugBank: Ziresovir (DB15145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Planned treatments are:~* Cohort 1: 300 mg of ziresovir~* Cohort 2: up to 600 mg of ziresovir~* Cohort 3: up to 900 mg of ziresovir
Trial: NCT05671081
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: patients will receive combined general anesthesia and bilateral bilevel at T5 \&T10 Erector spinae plane block with 20mL of bupivacaine 0.125 %. plus 0.5 μg/kgof Dexmedetomidine for each injection
Trial: NCT05671081
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: patients will receive combined general anesthesia and bilateral bilevel at T5 \&T10 Erector spinae plane block with 20mL of bupivacaine 0.125 %. plus 2 mg/kg Magnesium sulfate for each injection
Trial: NCT00000755
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05267431
Drug: Biological Drug
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Different biological drugs
Trial: NCT04831151
Drug: Yasmin
RxNorm normalized name: Yasmin
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Yasmin: 0,03 mg ethinylestradiol + 3 mg drospirenone
Trial: NCT04831151
Drug: Diane-35
RxNorm normalized name: Dianeal PD-2/2.5
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diane 35: 0,035 mg ethinylestradiol + 2 mg cyproterone acetate
Trial: NCT05607537
Drug: (14C)E7386 Capsule
RxNorm normalized name: urea [14C]
DrugBank: Urea C-13 (DB09510)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: (14C)E7386 40 mg capsule.
Trial: NCT05607537
Drug: (14C)E7386
RxNorm normalized name: urea [14C]
DrugBank: Urea C-13 (DB09510)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: (14C)E7386 administered intravenously.
Trial: NCT05540145
Drug: SOX plus Paclitaxel with or without antiangiogenesis followed by PD-1 antibody
RxNorm normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Drug: Paclitaxel(albumin-bound) 130mg/m2, ivgtt, D1, Q2w Drug: Oxaliplatin 70 mg/m2, ivgtt, D1, q2w Drug: S-1 40mg (body surface area \< 1.25m2), bid, D1-8, Q2w 50mg (body surface area \>1.25m2, \<1.5 m2), bid, D1-8, Q2w 60mg (body surface area \>1.5m2), bid, D1-8, Q2w Drug: Bevacizumab, 5mg/kg, ivgtt, D1, Q14d Drug: PD-1 antibody, 200mg, ivgtt, D1, Q21d Patients with Her-2 negative, MMR-proficient locally advanced esophagogastric junction or gastric adenocarcinoma will receive 6 cycles of neoadjuvant chemotherapy with or without antiangiogenesis. After comprehensive evaluations, patients who respond to chemotherapy will further receive 2 cycles of PD-1 antibody comibed with antiangiogenesis and chemotherapy as neoadjuvant therapy.~Drug: Pembrolizumab or sintilimab, 100\~200mg, ivgtt, D1, Q3w. Patients will make the final decision of PD -1 antibody according to their economic condition.
Trial: NCT05117853
Drug: Autofluorescent detection + Injection of indocyanine green
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All four parathyroid glands will be actively sought for in every case selected for the use of AF/ICG, with AF verification of parathyroid tissue.~The timepoints of AF will be:~* 1 = after lateral dissection side 1 (side 1)~* 2= after lateral dissection side 2 (side 2)~The timepoints of ICG injection will be:~* 1 = after the first thyroid lobectomy (side 1)~* 2 = after the second thyroid lobectomy (side 2)~Scoring of the viability of parathyroid glands (adapted from Vidal Fortuny et al., 2016):~* 1 = black = not viable/vascularized~* 2 = grey = moderately viably/ moderately vascularized~* 3 = white = viable/well-vascularized
Trial: NCT00002291
Drug: Pentamidine isethionate
RxNorm normalized name: Pentamidine Isethionate
DrugBank: Pentamidine (DB00738)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04846673
Drug: Pregabalin 150mg + Alpha-lipoic acid 480mg
RxNorm normalized name: Alpha lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin qd + alpha-lipoic acid qd
Trial: NCT04846673
Drug: Pregabalin 150mg
RxNorm normalized name: PREGABALIN 150MG CAP,UD
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: pregabalin qd
Trial: NCT04846673
Drug: Alpha-Lipoic Acid 480mg
RxNorm normalized name: Alpha lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha-lipoic acid qd
Trial: NCT05963867
Drug: BI 764532
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 764532
Trial: NCT04869228
Drug: GT0918 tablets or placebo
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO TAB
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: GT0918 tablets or placebo: oral, 1 time / day, 2 tablets / time, after meals
Trial: NCT05832580
Drug: Etidronate
RxNorm normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Etidronate in capsules of 200 mg or 400 mg.
Trial: NCT01241175
Drug: Magnesium Sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05795244
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: - Nivolumab 480 mg/every 4 weeks/IV infusion/6 cycles
Trial: NCT04648891
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection 0.5cc 2% in 1:100,000 epinephrine
Trial: NCT05564416
Drug: Erdafitinib
RxNorm normalized name: erdafitinib
DrugBank: Erdafitinib (DB12147)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT05210621
Drug: Ocrelizumab
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: ocrelizumab will be administered as single 600-mg infusions in 500 mL 0.9% sodium chloride every 24 weeks (±14 days) up to Week 192 (Year 4) of this study
Trial: NCT04886622
Drug: DT2216
RxNorm normalized name: DT2216
DrugBank: DT2216 (DB18020)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DT2216 will be administered by intravenous infusion
Trial: NCT04979650
Drug: Methylprednisolone succinate
RxNorm normalized name: Methylprednisolone succinate
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 gram of methylprednisolone succinate within 500 ccs of normal saline
Trial: NCT05577416
Drug: Part A: Safusidenib Erbumine
DrugBank: Erbumine (DB18019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part A: Safusidenib Erbumine orally 250 mg BID for 28 days.
Trial: NCT05577416
Drug: Part B: Safusidenib Erbumine
DrugBank: Erbumine (DB18019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part B: Safusidenib Erbumine orally 250 mg BID for 28 days for a minimum of 12, 28-day cycles subject to ongoing documented evidence of clinical benefit, until disease progression or unacceptable toxicity.
Trial: NCT05114239
Drug: Timolol 0.25% Ophthalmic Solution
RxNorm normalized name: Timolol 0.25% Ophthalmic Solution
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Applied to treatment side prior to standard wound care
Trial: NCT04833374
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive 0.5g/d methylprednisolone intravenously for 3 consecutive days in the 1st-2nd-3rd or 1st-3rd-5th month, then oral prednisone 0.5mg/kg/d on alternate days for 6 months.
Trial: NCT05087589
Drug: Tofacitinib
RxNorm normalized name: Tofacitinib
DrugBank: Tofacitinib (DB08895)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tofacitinib 5mg was taken orally twice a day for 6 months
Trial: NCT05081388
Drug: imdevimab
RxNorm normalized name: imdevimab
DrugBank: Imdevimab (DB15940)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: SC single dose
Trial: NCT05081388
Drug: casirivimab + imdevimab
RxNorm normalized name: casirivimab / imdevimab
DrugBank: Imdevimab (DB15940)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: SC single dose
Trial: NCT02658292
Drug: Naftifine hydrochloride foam, 3%
DrugBank: Naftifine (DB00735)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Apply NAFT900 foam twice daily to the affected area(s) plus half-inch around each affected area for 4 weeks
Trial: NCT04600154
Drug: MS-20
RxNorm normalized name: morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Specific fraction from fermented soy milk
Trial: NCT05327582
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered intravenously, 1000 mg on day 1 in a 3-week cycle
Trial: NCT05327582
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered orally, 8mg/d once daily in a 3-week cycle
Trial: NCT05327582
Drug: Nab paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered intravenously, 180-220 mg/m2 on day1 in a 3-week cycle
Trial: NCT05567081
Drug: Triamcinolone Acetonide 40mg/mL
RxNorm normalized name: TRIAMCINOLONE ACETONIDE 40MG/ML INJ,SUSP
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Deep perineural injection with 1cm corticosteroid mixed with 1ml lidocaine hydrochloride.
Trial: NCT05567081
Drug: PRP
RxNorm normalized name: PRP
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep perineural injection with 3ml PRP at the thickest part of the ulnar nerve.
Trial: NCT06410911
Drug: Sbcostal transversus Abdominis block and erector spinae block for both groups
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each patients group will recieve a type of block by injecting 20 ml of 0.25% bupivacaine on each side in patients undergoing open cholecystectomy
Trial: NCT06291077
Drug: Belatacept
RxNorm normalized name: Belatacept
DrugBank: Belatacept (DB06681)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Changing of anticalcineurins by Belatacept
Trial: NCT06244485
Drug: Valemetostat tosylate
RxNorm normalized name: tazemetostat
DrugBank: Valemetostat (DB18314)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered orally once daily
Trial: NCT06244485
Drug: T-DXd
RxNorm normalized name: T-5224
DrugBank: T-5224 (DB05998)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One IV infusion Q3W on Day 1 of each 21-day cycle
Trial: NCT06244485
Drug: Dato-DXd
RxNorm normalized name: Datopotamab deruxtecan
DrugBank: Datopotamab deruxtecan (DB16410)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One IV infusion Q3W on Day 1 of each 21-day cycle.
Trial: NCT06492941
Drug: Docetaxel for Injection (Albumin bound)
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel for Injection (Albumin bound), by intravenous infusion, every 3 weeks.
Trial: NCT05763459
Drug: ABBV-CLS-7262
RxNorm normalized name: ABBV-CLS-7262
DrugBank: ABBV-CLS-7262 (DB18407)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: ABBV-CLS-7262 Drug: Digoxin Drug: Rosuvastatin
Trial: NCT06390098
Drug: ASN51
RxNorm normalized name: Asparaginase
DrugBank: Asparaginase Escherichia coli (DB00023)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ASN51 formulation for oral capsule
Trial: NCT06162819
Drug: Amitriptyline
RxNorm normalized name: Amitriptyline
DrugBank: Amitriptyline (DB00321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amitriptyline will be used for prophylaxis of migraine, also used as antidepressant
Trial: NCT06162819
Drug: Flunarizine 5mg
RxNorm normalized name: flunarizine
DrugBank: Flunarizine (DB04841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunarizine will be used for prophylaxis of migraine,
Trial: NCT04752540
Drug: Olorofim
RxNorm normalized name: Olorofim
DrugBank: Olorofim (DB15245)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral dose
Trial: NCT00236028
Drug: Infliximab
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT04818333
Drug: SHR-A1811
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase 1 Drug: SHR-A1811 There are four pre-defined dose regimens . Subjects will be enrolled with an initial dose Phase 2 Drug: SHR-A1811 Doses will be determined from Phase 1
Trial: NCT04562779
Drug: Naltrexone 380 MG
RxNorm normalized name: naltrexone 380 MG
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: XR naltrexone to be given once prior to hospital discharge
Trial: NCT04562779
Drug: Ketamine Hydrochloride
RxNorm normalized name: Ketamine Hydrochloride
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV ketamine infusion to be given once prior to hospital discharge
Trial: NCT05103254
Drug: Bempedoic Acid
RxNorm normalized name: bempedoic acid
DrugBank: Bempedoic acid (DB11936)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bempedoic Acid 180 MG
Trial: NCT05103254
Drug: Bempedoic Acid / Ezetimibe
RxNorm normalized name: bempedoic acid / ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bempedoic Acid 180 MG / Ezetimibe 10 MG
Trial: NCT05107778
Drug: ih PEG-IFN α-2a
RxNorm normalized name: PEG-IFN alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ih PEG-IFN α-2a 180μg subcutaneous injection once a week.
Trial: NCT05107778
Drug: Entecavir
RxNorm normalized name: Entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Entecavir 0.5 mg orally once daily.
Trial: NCT04780438
Drug: Dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients rendomized in this arm will receive dapagliflozin at a target dose of 10mg once daily.
Trial: NCT05790330
Drug: Dupilumab
RxNorm normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: As per usual standard of care
Trial: NCT05934097
Drug: FT596
RxNorm normalized name: Fezolinetant
DrugBank: Fezolinetant (DB15669)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosing to be initiated at a dose no higher than highest tolerable dose in study FT596-101, intravenously
Trial: NCT04472000
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study participants in the verum group receive one capsule of Burgerstein Vitamin C retard 500mg b.i.d. with treatment starting in the evening on the day of the operation for a total of 50 days.
Trial: NCT05934097
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.4 mg/m\^2 (maximum dose 2 mg) intravenously
Trial: NCT05934097
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg orally
Trial: NCT05934097
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 375 mg/m\^2 intravenously
Trial: NCT05934097
Drug: Bendamustine
RxNorm normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 90 mg/m\^2 IV infusion
Trial: NCT06021119
Drug: Dipeptidyl peptidase-4 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dipeptidyl peptidase-4 inhibitors with Iftar meal
Trial: NCT00006152
Drug: Ritonavir
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00006152
Drug: Abacavir sulfate
RxNorm normalized name: Abacavir Sulfate
DrugBank: Abacavir (DB01048)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00006152
Drug: Amprenavir
RxNorm normalized name: Amprenavir
DrugBank: Amprenavir (DB00701)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT06043752
Drug: Remsima
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The patient will be given one Injection of REMSIMA 120 mg subcutaneously at week 0, 1, 2, 3, 4 and then every 2 weeks i.e., at 6, 8, 10 and 14 weeks. If the weight of the patient is \>80 kg, 2 injections will be given.
Trial: NCT06253598
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenvatinib was administered orally once daily started on day 1 of cycle 1 of the study until disease progression or unacceptable toxicity occurred or meet the end point of the study. For patients weighing less than 60 kg, the recommended daily dose was 8 mg once daily. For patients weighing ≥60 kg, the recommended daily dose was 12 mg once daily
Trial: NCT06253598
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tislelizumab 200mg was administered intravenously every 3 week started on day 1 of cycle 3 until disease progression or unacceptable toxicity occurred or meet the end point of the study.
Trial: NCT00244686
Drug: Mepolizumab
RxNorm normalized name: Mepolizumab
DrugBank: Mepolizumab (DB06612)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: open label investigational product
Trial: NCT06041048
Drug: Modafinil
RxNorm normalized name: Modafinil
DrugBank: Modafinil (DB00745)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single dose (200 mg) of medication versus placebo given to healthy control subjects
Trial: NCT04133506
Drug: Aspirin 300mg
RxNorm normalized name: ASPIRIN 300MG TAB
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: see earlier (only half of healthy volunteers receive aspirin)
Trial: NCT06207955
Drug: TMJ Arthrocentesis Followed By Injectable Platelet Rich Fibrin And Botulinum Toxin Type A
RxNorm normalized name: botulinum toxin type A Injection
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: TMJ Arthrocentesis I-PRF Intra-articular Injection Botulinum Toxin Type A to Lateral Pterygoid Muscle
Trial: NCT06207955
Drug: TMJ Arthrocentesis Followed By Injectable Platelet Rich Fibrin
RxNorm normalized name: Platelet Rich Plasma
DrugBank: Fibrin (DB16604)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMJ Arthrocentesis I-PRF Intra-articular Injection
Trial: NCT06610734
Drug: Adebrelimab
RxNorm normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adebrelimab combined with chemotherapy synchronous LDRT
Trial: NCT06609551
Drug: 6-month adjuvant chemotherapy with 5-FU monotherapy
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 6 months of adjuvant chemotherapy with 5-FU monotherapy. The follow-up strategy for the four groups of subjects will be the same, including but not limited to chest plain or enhanced CT, abdominal/pelvic enhanced CT, and detection of the tumor marker carcinoembryonic antigen (CEA), until disease progression occurs. All patients will undergo peripheral blood ctDNA-MRD testing again six months after surgery.